MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

Abstract Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous clonal disease associated with unmet medical needs. Paralleling the pathology of other cancers, AML tumorigenesis and propagation can be ascribed to dysregulated cellular processes, including apoptosis. This function...

Full description

Bibliographic Details
Main Authors: Douglas D. Fang, Qiuqiong Tang, Yanhui Kong, Tao Rong, Qixin Wang, Na Li, Xu Fang, Jiaxing Gu, Dengkun Xiong, Yan Yin, Jing Deng, Dajun Yang, Yifan Zhai
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-021-00465-5

Internet

https://doi.org/10.1038/s41420-021-00465-5

Similar Items